✦ LIBER ✦

Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens

✍ Scribed by Gangal, S G; Damle, N K; Khare, A G; Advani, S H

Book ID: 109834893
Publisher: Nature Publishing Group
Year: 1979
Tongue: English
Weight: 834 KB
Volume: 40
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1979.193

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rapid generation of antigen-presenting c

Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia

✍ Theresia M. Westers; Anita G. Stam; Rik J. Scheper; Johanna C. Regelink; Aggie W 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 378 KB

In vitro generation of lymphocytotoxicit

In vitro generation of lymphocytotoxicity to autochthonous leukaemic cells in chronic myeloid leukaemia

✍ Khare, A G; Advani, S H; Gangal, S G 📂 Article 📅 1981 🏛 Nature Publishing Group 🌐 English ⚖ 855 KB

Sequential mutations causing resistance

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis

✍ Fabio Stagno; Stefania Stella; Salvatore Berretta; Michele Massimino; Agostino A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Interferon alpha in combination with GM-

Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia

✍ Xiao Chen; Sybille Regn; Silke Raffegerst; Hans-Jochem Kolb; Marie Roskrow 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 807 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

Intensive chemotherapy and autologous he

Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia

✍ Passweg, J R; Gratwohl, A; Heim, D; Friess, D; Christen, S; Stüssi, G; Meyer-Mon 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 84 KB